INC. (NASDAQ:INCR) Files An 8-K Other EventsITEM 8.01Other Events
On August 16, 2018, McorpCX, Inc. (the “Company”) issued a press release describing the Company’s financial results for the quarter and year to date period ended June 30, 2018 as well as certain organizational changes for the Company that were approved by the Board of Directors on August 16, 2018.
A copy of the press release is included with this Form 8-K as Exhibit 99.1.
ITEM 9.01Exhibits
99.1 Press release dated August 16, 2018.
McorpCX, Inc. ExhibitEX-99.1 2 ex_122068.htm EXHIBIT 99.1 ex_122068.htm Exhibit 99.1 McorpCX,…To view the full exhibit click here
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
